Uncategorized

FDA rejects Unicycive and Sobi filings over contract manufacturing deficiencies

Published

on

Unicycive Therapeutics and Sobi received complete response letters for kidney disease and gout filings, respectively, after the FDA found fault with their manufacturing partners.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version